rs11104986 - RNU1-117P - LINC02458

Magnitude 4.5 · 1 study on file

Reported associations

• Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria - Unknown journal (n.d.) · Unknown authors · PubMed 32433338

  ABSTRACT: Supplemental Digital Content is available in the text. Plasmodium vivax has the largest geographic range of human malaria species and is challenging to manage and eradicate due to its ability to establish a dormant liver stage, the hypnozoite, which can reactivate leading to relapse. Until recently, the only treatment approved to kill hypnozoites was the 8-aminoquinoline, primaquine, requiring daily treatment for 14 days. Tafenoquine, an 8-aminoquinoline single-dose treatment with activity against P. vivax hypnozoites, has recently been approved by the US Food and Drug Administration and Australian Therapeutic Goods Administration for the radical cure of P. vivax malaria in patients 16 years and older. We conducted an exploratory pharmacogenetic analysis (GSK Study 208099) to

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.